tiprankstipranks
Vigil Neuroscience Advances Alzheimer’s Trial, Eyes 2025 Data
PremiumCompany AnnouncementsVigil Neuroscience Advances Alzheimer’s Trial, Eyes 2025 Data
3M ago
Vigil Neuroscience announces FDA removed partial clinical hold on VG-3927
Premium
The Fly
Vigil Neuroscience announces FDA removed partial clinical hold on VG-3927
3M ago
Vigil Neuroscience price target lowered to $16 from $17 at Guggenheim
Premium
The Fly
Vigil Neuroscience price target lowered to $16 from $17 at Guggenheim
4M ago
Vigil Neuroscience announces interim data from ongoing Phase 1 trial on VG-3927
PremiumThe FlyVigil Neuroscience announces interim data from ongoing Phase 1 trial on VG-3927
5M ago
Vigil Neuroscience price target lowered to $17 from $24 at H.C. Wainwright
Premium
The Fly
Vigil Neuroscience price target lowered to $17 from $24 at H.C. Wainwright
5M ago
Vigil Neuroscience Advances IGNITE Trial, Eyes Accelerated Approval
Premium
Company Announcements
Vigil Neuroscience Advances IGNITE Trial, Eyes Accelerated Approval
5M ago
These 2 ‘Strong Buy’ Penny Stocks Are Poised for a Massive Rally, Say Analysts
PremiumStock Analysis & IdeasThese 2 ‘Strong Buy’ Penny Stocks Are Poised for a Massive Rally, Say Analysts
7M ago
Vigil Neuroscience reports Q1 EPS (50c), consensus (61c)
Premium
The Fly
Vigil Neuroscience reports Q1 EPS (50c), consensus (61c)
8M ago
Vigil says interim IGNITE Phase 2 data demonstrate VGL101 potential for ALSP
Premium
The Fly
Vigil says interim IGNITE Phase 2 data demonstrate VGL101 potential for ALSP
8M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100